Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients

Autor Lasnon, Charline, Desmonts, Cédric, Quak, Elske, Gervais, Radj, Do, Pascal, Dubos-Arvis, Catherine, Aide, Nicolas
Vydáno 2013

Off-Label Use of Crizotinib as a Neoadjuvant Treatment for a Young Patient When Conventional Chemotherapy Gave No Benefits in Stage IIIA Non-Small Cell Lung Cancer

Autor Dumont, Delphine, Dô, Pascal, Lerouge, Delphine, Planchard, Gaëtane, Riffet, Marc, Dubos-Arvis, Catherine, Danhier, Serge, Gervais, Radj
Vydáno v Am J Case Rep (2017)

Oxaliplatin-induced bronchiolitis obliterans organizing pneumonia following hyperthermic intraperitoneal chemotherapy

Autor Le Baut, Guillaume, Guilloit, Jean-Marc, Leprince, Vincent, Ollivier, Yann, Dubos-Arvis, Catherine, Do, Pascal, Sutter, Jasmine, Loge, Ludovic, Gervais, Radj
Vydáno v J Gastrointest Oncol (2018)

Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02–14

Autor Auliac, Jean-Bernard, Dô, Pascal, Bayle, Sophie, Doubre, Hélène, Vinas, Florent, Letreut, Jacques, Falchero, Lionel, Hauss, Pierre Alexandre, Thomas, Pascal, Chouaid, Christos
Vydáno v Adv Ther (2019)

Safety of combined PD‐1 pathway inhibition and radiation therapy for non‐small‐cell lung cancer: A multicentric retrospective study from the GFPC

Autor Lesueur, Paul, Escande, Alexandre, Thariat, Juliette, Vauléon, Enora, Monnet, Isabelle, Cortot, Alexis, Lerouge, Delphine, Danhier, Serge, Dô, Pascal, Dubos‐Arvis, Catherine, Chouaïd, Christos, Gervais, Radj
Vydáno v Cancer Med (2018)

Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL stud...

Autor Bennouna, Jaafar, Barlesi, Fabrice, Do, Pascal, Dumont, Patrick, Cadranel, Jacques, Debieuvre, Didier, Hilgers, Werner, Molinier, Olivier, Quoix, Elisabeth, Raimbourg, Judith, Langlais, Alexandra, Morin, Franck, Souquet, Pierre-Jean
Vydáno v ESMO Open (2018)

Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04)

Autor Vergnenegre, Alain, Geier, Margaux, Guisier, Florian, Lamy, Regine, Comet, Bénédicte, Le Garff, Gwenaelle, Do, Pascal, Janicot, Henri, Morel, Hugues, Decroisette, Chantal, Andre, Michel, Falchero, Lionel, Paleiron, Nicolas, Monnet, Isabelle
Vydáno v Cancer Med (2019)

Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019

Autor Auliac, Jean-Bernard, Bayle, Sophie, Do, Pascal, Le Garff, Gwenaëlle, Roa, Magali, Falchero, Lionel, Huchot, Eric, Quéré, Gilles, Jeannin, Gaëlle, Métivier, Anne-Cécile, Hobeika, Joëlle, Guisier, Florian, Chouaid, Christos
Vydáno v Cancers (Basel) (2020)

Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy f...

Autor Borget, Isabelle, Pérol, Maurice, Pérol, David, Lavolé, Armelle, Greillier, Laurent, Dô, Pascal, Westeel, Virginie, Crequit, Jacky, Léna, Hervé, Monnet, Isabelle, Le Caer, Hervé, Fournel, Pierre, Falchero, Lionel, Poudenx, Michel, Vaylet, Fabien, Chabaud, Sylvie, Vergnenegre, Alain, Zalcman, Gérard, Chouaïd, Christos
Vydáno v BMC Cancer (2014)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors

Autor Baldacci, Simon, Mazieres, Julien, Tomasini, Pascale, Girard, Nicolas, Guisier, Florian, Audigier-Valette, Clarisse, Monnet, Isabelle, Wislez, Marie, Pérol, Maurice, Dô, Pascal, Dansin, Eric, Leduc, Charlotte, Giroux Leprieur, Etienne, Moro-Sibilot, Denis, Tulasne, David, Kherrouche, Zoulika, Labreuche, Julien, Cortot, Alexis B.
Vydáno v Oncotarget (2017)

Real-life experience of ceritinib in crizotinib-pretreated ALK(+) advanced non-small cell lung cancer patients

Autor Cadranel, Jacques, Cortot, Alexis B., Lena, Hervé, Mennecier, Bertrand, Do, Pascal, Dansin, Eric, Mazieres, Julien, Chouaid, Christos, Perol, Maurice, Barlesi, Fabrice, Robinet, Gilles, Friard, Sylvie, Thiberville, Luc, Audigier-Valette, Clarisse, Vergnenegre, Alain, Westeel, Virginie, Slimane, Khemaies, Buturuga, Alexandru, Moro-Sibilot, Denis, Besse, Benjamin
Vydáno v ERJ Open Res (2018)

Utility of serum anti‐cetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab

Autor Dupont, Benoît, Mariotte, Delphine, Dugué, Audrey E., Clarisse, Bénédicte, Grellard, Jean‐Michel, Babin, Emmanuel, Chauffert, Bruno, Dakpé, Stéphanie, Moldovan, Cristian, Bouhier‐Leporrier, Karine, Reimund, Jean‐Marie, Di Fiore, Frederic, Zanetta, Sylvie, Mailliez, Audrey, Do, Pascal, Peytier, Annie, Galais, Marie‐Pierre, Florescu, Carmen, Schott, Roland, Le Mauff, Brigitte, Gervais, Radj
Vydáno v Br J Clin Pharmacol (2016)